• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲国家卫生技术评估系统非排名分类与比较的原型开发。

Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.

作者信息

Allen Nicola, Pichler Franz, Wang Tina, Patel Sundip, Salek Sam

机构信息

Centre for Socioeconomic Research, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, UK; Centre for Innovation in Regulatory Science (formerly CMR International Institute for Regulatory Science), Hatton Garden, London EC1N 8JS, UK.

出版信息

Health Policy. 2013 Dec;113(3):305-12. doi: 10.1016/j.healthpol.2013.09.007. Epub 2013 Sep 25.

DOI:10.1016/j.healthpol.2013.09.007
PMID:24176288
Abstract

INTRODUCTION

European countries are increasingly utilising health technology assessment (HTA) to inform reimbursement decision-making. However, the current European HTA environment is very diverse, and projects are already underway to initiate a more efficient and aligned HTA practice within Europe. This study aims to identify a non-ranking method for classifying the diversity of European HTA agencies process and the organisational architecture of the national regulatory review to reimbursement systems.

METHOD/RESULTS: Using a previously developed mapping methodology, this research created process maps to describe national processes for regulatory review to reimbursement for 33 European jurisdictions. These process maps enabled the creation of 2 HTA taxonomic sets. The confluence of the two taxonomic sets was subsequently cross-referenced to identify 10 HTA archetype groups.

DISCUSSION

HTA is a young, rapidly evolving field and it can be argued that optimal practices for performing HTA are yet to emerge. Therefore, a non-ranking classification approach could objectively characterise and compare the diversity observed in the current European HTA environment.

摘要

引言

欧洲国家越来越多地利用卫生技术评估(HTA)来为报销决策提供依据。然而,当前欧洲的HTA环境非常多样化,目前已经在开展一些项目,以在欧洲建立更高效、更统一的HTA实践。本研究旨在确定一种非排名方法,用于对欧洲HTA机构流程的多样性以及国家监管审查至报销系统的组织结构进行分类。

方法/结果:本研究采用先前开发的映射方法,创建了流程地图,以描述33个欧洲司法管辖区从监管审查到报销的国家流程。这些流程地图促成了两个HTA分类集的创建。随后,对这两个分类集的交集进行交叉引用,以识别出10个HTA原型组。

讨论

HTA是一个年轻且快速发展的领域,可以说执行HTA的最佳实践尚未出现。因此,一种非排名的分类方法可以客观地描述和比较当前欧洲HTA环境中观察到的多样性。

相似文献

1
Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.欧洲国家卫生技术评估系统非排名分类与比较的原型开发。
Health Policy. 2013 Dec;113(3):305-12. doi: 10.1016/j.healthpol.2013.09.007. Epub 2013 Sep 25.
2
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?欧洲卫生技术评估机构报销建议的比较:是否有进一步协调的机会?
Front Pharmacol. 2017 Jun 30;8:384. doi: 10.3389/fphar.2017.00384. eCollection 2017.
3
Health technology assessment of medical devices: What is different? An overview of three European projects.医疗设备的卫生技术评估:有何不同?三个欧洲项目概述。
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):309-18. doi: 10.1016/j.zefq.2015.06.011. Epub 2015 Jul 26.
4
The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.健康技术评估在选定中等收入国家药品报销中的作用。
Health Policy. 2010 May;95(2-3):174-84. doi: 10.1016/j.healthpol.2009.12.008. Epub 2010 Jan 13.
5
The role of health technology assessment in coverage decisions on newborn screening.健康技术评估在新生儿筛查覆盖决策中的作用。
Int J Technol Assess Health Care. 2011 Oct;27(4):313-21. doi: 10.1017/S0266462311000468.
6
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
7
Health technology assessment.卫生技术评估
Q J Nucl Med. 2000 Jun;44(2):105-11.
8
Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.在欧洲进行卫生技术评估的实用工具和方法:欧洲卫生技术评估网络(EUnetHTA)制定的结构、方法和工具。
Int J Technol Assess Health Care. 2009 Dec;25 Suppl 2:1-8. doi: 10.1017/S0266462309990626.
9
Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?卫生技术评估在政策制定中的传播和应用:对分散的医疗保健系统有哪些借鉴意义?
Health Policy. 2012 Dec;108(2-3):194-202. doi: 10.1016/j.healthpol.2012.09.017. Epub 2012 Oct 23.
10
Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.卫生技术评估(HTA)中真实世界数据的使用政策:六个HTA机构的比较研究
Value Health. 2017 Apr;20(4):520-532. doi: 10.1016/j.jval.2016.12.003. Epub 2017 Jan 27.

引用本文的文献

1
Preparing for the EU HTA Regulation: Insights from the Dutch Perspective.为欧盟卫生技术评估法规做准备:来自荷兰视角的见解。
J Mark Access Health Policy. 2025 Jul 24;13(3):35. doi: 10.3390/jmahp13030035. eCollection 2025 Sep.
2
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.管理准入协议在不同环境和组合下对创新疗法的应用:可行性分析。
Int J Environ Res Public Health. 2020 Nov 10;17(22):8309. doi: 10.3390/ijerph17228309.
3
Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
全球范围内的卫生技术评估中的循证决策过程:探索卫生技术评估的下一个前沿和最佳实践 评“全球卫生技术评估机构使用循证决策过程”。
Int J Health Policy Manag. 2021 Mar 14;10(4):232-236. doi: 10.34172/ijhpm.2020.145.
4
Archetype analysis of older adult immunization decision-making and implementation in 34 countries.34 个国家老年人免疫接种决策和实施的原型分析。
Vaccine. 2020 May 27;38(26):4170-4182. doi: 10.1016/j.vaccine.2020.04.027. Epub 2020 Apr 16.
5
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?欧洲卫生技术评估机构报销建议的比较:是否有进一步协调的机会?
Front Pharmacol. 2017 Jun 30;8:384. doi: 10.3389/fphar.2017.00384. eCollection 2017.
6
Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.评估加拿大药品通用审查报销建议与省级药品计划列入决策之间的一致性:一项探索性研究。
CMAJ Open. 2016 Nov 3;4(4):E674-E678. doi: 10.9778/cmajo.20160006. eCollection 2016 Oct-Dec.
7
HTA Implementation Roadmap in Central and Eastern European Countries.中东欧国家的卫生技术评估实施路线图。
Health Econ. 2016 Feb;25 Suppl 1(Suppl Suppl 1):179-92. doi: 10.1002/hec.3298. Epub 2016 Jan 14.
8
From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.从市场准入到患者准入:36个欧洲国家药品报销与定价的循证方法概述
Health Res Policy Syst. 2015 Sep 25;13:39. doi: 10.1186/s12961-015-0028-5.
9
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.波兰、捷克共和国、匈牙利、罗马尼亚和保加利亚的卫生技术评估。
Eur J Health Econ. 2014 May;15 Suppl 1:S13-25. doi: 10.1007/s10198-014-0590-8. Epub 2014 May 16.